Advanced Enzyme Technologies Ltd vs Jubilant Pharmova Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 05, 2026

Key Highlights

The Latest Trading Price of Advanced Enzyme Technologies Ltd is ₹ 357.1 as of 05 May 15:30 . The P/E Ratio of Advanced Enzyme Technologies Ltd changed from 26.4 on March 2021 to 23.8 on March 2025 . This represents a CAGR of -2.05% over 5 yearsThe P/E Ratio of Jubilant Pharmova Ltd changed from 13 on March 2021 to 16.8 on March 2025 . This represents a CAGR of 5.26% over 5 years The Market Cap of Advanced Enzyme Technologies Ltd changed from ₹ 3852 crore on March 2021 to ₹ 3120 crore on March 2025 . This represents a CAGR of -4.13% over 5 yearsThe Market Cap of Jubilant Pharmova Ltd changed from ₹ 10838 crore on March 2021 to ₹ 14220 crore on March 2025 . This represents a CAGR of 5.58% over 5 years The revenue of Advanced Enzyme Technologies Ltd for the Dec '25 is ₹ 191.66 crore as compare to the Sep '25 revenue of ₹ 194.81 crore. This represent the decline of -1.62% The revenue of Jubilant Pharmova Ltd for the Dec '25 is ₹ 2143 crore as compare to the Sep '25 revenue of ₹ 1976 crore. This represent the growth of 8.44% The ebitda of Advanced Enzyme Technologies Ltd for the Dec '25 is ₹ 69.07 crore as compare to the Sep '25 ebitda of ₹ 70.34 crore. This represent the decline of -1.81% The ebitda of Jubilant Pharmova Ltd for the Dec '25 is ₹ 270.2 crore as compare to the Sep '25 ebitda of ₹ 345.3 crore. This represent the decline of -21.75% The net profit of Advanced Enzyme Technologies Ltd changed from ₹ 34.98 crore to ₹ 43.18 crore over 7 quarters. This represents a CAGR of 12.79% The net profit of Jubilant Pharmova Ltd changed from ₹ 481.8 crore to ₹ 55.8 crore over 7 quarters. This represents a CAGR of -70.83% The Dividend Payout of Advanced Enzyme Technologies Ltd changed from 14.16 % on March 2021 to 56.81 % on March 2025 . This represents a CAGR of 32.03% over 5 yearsThe Dividend Payout of Jubilant Pharmova Ltd changed from 37.14 % on March 2021 to 414.06 % on March 2025 . This represents a CAGR of 61.97% over 5 years .

About Advanced Enzyme Technologies Ltd

Advanced Enzyme Technologies Limited (AETL) is largest Indian enzyme company that transformed business globally in the manufacturing and sale of enzymes.
The Company was incorporated, as a Private Company on March 15, 1989 as 'Advanced Biochemicals Private Limited' in Maharashtra.
It thereafter converted the status into a Public Company and the name of the Company was changed to Advanced Biochemicals Limited on May 28, 1992 and further was changed to Advanced Enzyme Technologies Limited via fresh Certificate of Incorporation at RoC, Mumbai on August 19, 2005. In 2011, the company took over Cal-India Foods International, giving the company direct presence in USA. In 2012, the company took over Advanced Supplementary Technologies Corporation for consolidating its presence in USA. Advanced Enzyme Technologies Limited came out with its Initial Public Offer (IPO) of 4,594,875 Equity shares of Rs 10 each at an issue price of Rs 896 per Equity share ( Rs 810 per Equity share for eligible employees), consisting of fresh issue of 560,405 Equity shares and an Offer for Sale of 4,034,470 Equity shares by Selling Shareholders.

About Jubilant Pharmova Ltd

Jubilant Pharmova Limited was initially incorporated as 'Vam Organic Chemicals Limited' on June 21, 1978.
Company name was changed to 'Jubliant Organosys Limited' in November, 2001 and was again changed to 'Jubilant Life Sciences Limited' in October, 2009 and further it attained a new name 'Jubilant Pharmova Limited' in February, 2021. Jubilant Pharmova Limited is an integrated global pharmaceutical and life sciences company engaged in Pharmaceuticals, Life Science Ingredients and Drug Discovery Solutions.
The Company is engaged in pharmaceuticals, contract research and development services and proprietary novel drugs.
The pharmaceuticals segment, through wholly owned subsidiary Jubilant Pharma Limited, is engaged in manufacture and supply of Active Pharmaceutical Ingredients (APIs), Solid Dosage Formulations, Radiopharmaceuticals, Allergy Therapy Products and Contract Manufacturing of Sterile Injectables and Non-Sterile Products through 6 US FDA approved manufacturing facilities in India, USA and Canada with a network of over 48 radiopharmacies in the USA.

FAQs for the comparison of Advanced Enzyme Technologies Ltd and Jubilant Pharmova Ltd

Which company has a larger market capitalization, Advanced Enzyme Technologies Ltd or Jubilant Pharmova Ltd?

Market cap of Advanced Enzyme Technologies Ltd is 3,996 Cr while Market cap of Jubilant Pharmova Ltd is 14,950 Cr

What are the key factors driving the stock performance of Advanced Enzyme Technologies Ltd and Jubilant Pharmova Ltd?

The stock performance of Advanced Enzyme Technologies Ltd and Jubilant Pharmova Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Advanced Enzyme Technologies Ltd and Jubilant Pharmova Ltd?

As of May 5, 2026, the Advanced Enzyme Technologies Ltd stock price is INR ₹357.1. On the other hand, Jubilant Pharmova Ltd stock price is INR ₹938.5.

How do dividend payouts of Advanced Enzyme Technologies Ltd and Jubilant Pharmova Ltd compare?

To compare the dividend payouts of Advanced Enzyme Technologies Ltd and Jubilant Pharmova Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.